Skip to main content

Todos Medical's Letter of Intent with Provista Diagnostics set to license sepsis diagnostic testing

--News Direct--

Todos Medical president and CEO Gerald Commissiong joins Proactive's Natalie Stoberman to discuss news of the company entering a Letter of Intent with Provista Diagnostics to license PCR-based sepsis diagnostic test AcuSept LDT rights From Acumen Diagnostics.

Todos Medical engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma.

Contact Details

Proactive Investors

+1 347-449-0879

View source version on

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.